Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.

If you're interested, check out the recording here while the link's still up.

Bhaskar Chaudhuri net worth and biography

Bhaskar Chaudhuri Biography and Net Worth

Director of Arcutis Biotherapeutics

Dr. Chaudhuri has been an Operating Partner at Frazier Healthcare since 2011, focusing on investments in later-stage companies and in international opportunities. Prior to joining Frazier, he was President of Valeant Pharmaceuticals (currently Bausch Health), where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Dow focused on dermatology drug development and commercialization and was the source of multiple approved products. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Mylan subsidiary Bertek Pharmaceuticals, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm as VP of R&D. In addition to Arcutis, he also serves on the board of Silvergate Pharmaceuticals (private) and Teligent (NASDAQ: TLGT). He also serves on the Advisory Board of the Johns Hopkins Berman Institute of Bioethics. He holds a Ph.D. from the University of Louisiana, a M.S. and a B.S. in Pharmacy from Jadavpur University, India.

What is Bhaskar Chaudhuri's net worth?: The estimated net worth of Bhaskar Chaudhuri is at least $7.85 million as of June 24th, 2021. Dr. Chaudhuri owns 848,146 shares of Arcutis Biotherapeutics stock worth more than $7,853,832 as of November 17th. This net worth estimate does not reflect any other assets that Dr. Chaudhuri may own. Additionally, Dr. Chaudhuri receives an annual salary of $60,830.00 as Director at Arcutis Biotherapeutics. Learn More about Bhaskar Chaudhuri's net worth.
How old is Bhaskar Chaudhuri?: Dr. Chaudhuri is currently 69 years old. There are 6 older executives and no younger executives at Arcutis Biotherapeutics. Learn More on Bhaskar Chaudhuri's age.
What is Bhaskar Chaudhuri's salary?: As the Director of Arcutis Biotherapeutics, Inc., Dr. Chaudhuri earns $60,830.00 per year. There are 4 executives that earn more than Dr. Chaudhuri. The highest earning executive at Arcutis Biotherapeutics is Mr. Todd Franklin Watanabe M.A., President, CEO & Director, who commands a salary of $1,010,000.00 per year. Learn More on Bhaskar Chaudhuri's salary.
How do I contact Bhaskar Chaudhuri?: The corporate mailing address for Dr. Chaudhuri and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Bhaskar Chaudhuri's contact information.
Has Bhaskar Chaudhuri been buying or selling shares of Arcutis Biotherapeutics?: Bhaskar Chaudhuri has not been actively trading shares of Arcutis Biotherapeutics over the course of the past ninety days. Most recently, Bhaskar Chaudhuri sold 729 shares of the business's stock in a transaction on Thursday, June 24th. The shares were sold at an average price of $27.50, for a transaction totalling $20,047.50. Following the completion of the sale, the director now directly owns 848,146 shares of the company's stock, valued at $23,324,015. Learn More on Bhaskar Chaudhuri's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, insiders at the sold shares 17 times. They sold a total of 125,351 shares worth more than $1,161,310.05. The most recent insider tranaction occured on November, 11th when Director Terrie Curran sold 8,687 shares worth more than $94,253.95. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 11/11/2024.

Bhaskar Chaudhuri Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2021	Sell	729	$27.50	$20,047.50	848,146
6/21/2021	Sell	2,516	$27.50	$69,190.00	848,875
4/20/2021	Sell	10,000	$28.06	$280,600.00	862,671
3/22/2021	Sell	10,000	$31.10	$311,000.00	876,383
2/1/2021	Sell	9,949	$33.25	$330,804.25	901,340
1/29/2021	Sell	51	$27.50	$1,402.50	901,340

Bhaskar Chaudhuri Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $9.26

$9.11

$10.04

50 Day Range

MA: $9.62

$8.31

$10.87

2 Week Range

Now: $9.26

$1.76

$13.17

Volume

3,018,887 shs

Average Volume

2,360,436 shs

Market Capitalization

$1.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Why buying gold might be a mistake

From DTI | Ad

If you're interested, check out the recording here while the link's still up.

Bhaskar Chaudhuri Biography and Net Worth

What is Bhaskar Chaudhuri's net worth?

How old is Bhaskar Chaudhuri?

What is Bhaskar Chaudhuri's salary?

How do I contact Bhaskar Chaudhuri?

Has Bhaskar Chaudhuri been buying or selling shares of Arcutis Biotherapeutics?

Who are Arcutis Biotherapeutics' active insiders?

Are insiders buying or selling shares of Arcutis Biotherapeutics?